1. Home
  2. CKPT vs BNED Comparison

CKPT vs BNED Comparison

Compare CKPT & BNED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • BNED
  • Stock Information
  • Founded
  • CKPT 2014
  • BNED 1965
  • Country
  • CKPT United States
  • BNED United States
  • Employees
  • CKPT N/A
  • BNED N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • BNED Other Specialty Stores
  • Sector
  • CKPT Health Care
  • BNED Consumer Discretionary
  • Exchange
  • CKPT Nasdaq
  • BNED Nasdaq
  • Market Cap
  • CKPT 361.1M
  • BNED 371.2M
  • IPO Year
  • CKPT 2017
  • BNED N/A
  • Fundamental
  • Price
  • CKPT $4.26
  • BNED $12.03
  • Analyst Decision
  • CKPT Buy
  • BNED Hold
  • Analyst Count
  • CKPT 3
  • BNED 1
  • Target Price
  • CKPT $4.33
  • BNED N/A
  • AVG Volume (30 Days)
  • CKPT 2.1M
  • BNED 365.7K
  • Earning Date
  • CKPT 05-13-2025
  • BNED 06-30-2025
  • Dividend Yield
  • CKPT N/A
  • BNED N/A
  • EPS Growth
  • CKPT N/A
  • BNED N/A
  • EPS
  • CKPT N/A
  • BNED N/A
  • Revenue
  • CKPT $41,000.00
  • BNED $1,567,800,000.00
  • Revenue This Year
  • CKPT $102,182.93
  • BNED $2.74
  • Revenue Next Year
  • CKPT $351.71
  • BNED N/A
  • P/E Ratio
  • CKPT N/A
  • BNED N/A
  • Revenue Growth
  • CKPT N/A
  • BNED N/A
  • 52 Week Low
  • CKPT $1.80
  • BNED $6.05
  • 52 Week High
  • CKPT $4.50
  • BNED $81.28
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 80.26
  • BNED 70.50
  • Support Level
  • CKPT $4.14
  • BNED $10.33
  • Resistance Level
  • CKPT $4.20
  • BNED $11.25
  • Average True Range (ATR)
  • CKPT 0.03
  • BNED 0.49
  • MACD
  • CKPT -0.00
  • BNED 0.10
  • Stochastic Oscillator
  • CKPT 85.71
  • BNED 92.90

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is an operator of bookstores in college and university campuses across the United States. The company is also engaged in providing digital education services. It operates in three reportable segments that include Retail offers existing and prospective clients the flexibility of physical, virtual, or custom store solutions, and wholesale is comprised of the wholesale and virtual retail fulfillment, and support operations of the MBS subsidiary, also Corporate Services represent unallocated shared-service costs which include corporate level expenses and other governance functions, including executive functions, such as accounting, legal, treasury, information technology, and human resources. It earns majority of the revenue from Retail segment.

Share on Social Networks: